Drug Trial Radar · NCT07796256
Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 31, 2026
Primary completion
Aug 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Suzhou Sanegene Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-Label Phase II study to evaluate the efficacy and safety of multiple doses of SGB-9768 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Conditions
- PNH - Paroxysmal Nocturnal Hemoglobinuria
Interventions
SGB-9768Drug
SGB-9768 will be administered by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean LDH change from baselineTime frame: weeks 18-24
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.